REGN News and Press, Regeneron Pharmaceuticals Inc. From 03/12/24

2024-03-12 13:35:31 ET Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024, 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts ...

2024-03-11 07:52:45 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high cholesterol.... Read the full article on Seeking A...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowe...

2024-03-10 13:00:53 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat Cata...

2024-03-09 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-08 08:15:00 ET Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF , which tracks an industry index, is up by nearly 13% year to date. Still, it's too...

Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year EYLEA HD has shown impre...

2024-03-06 16:13:40 ET Summary Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively. Company has potential to overcom...

2024-03-06 15:33:05 ET Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 44th Annual Health Care Conference March 06, 2024 11:10 AM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - SVP and Head of IR Conference Call Participants Tyler...

2024-02-28 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...